Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations

Journal of Steroid Biochemistry and Molecular Biology

Volumn 65, Issue 1-6, 1998, Pages 181-189

  Tonetti, Debra A ^a   O'Regan, Ruth ^a   Tanjore, Shashikala ^a   England, Gale ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DNA; PROTEIN KINASE C; TAMOXIFEN; TOREMIFENE;

ANIMAL CELL; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; GROWTH STIMULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSTMENOPAUSE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PROTEIN KINASE C; TAMOXIFEN; TOREMIFENE; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032052776     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00011-9     Document Type: Conference Paper

References (43)

1. Early Breast Cancer Trialist' Collaboration Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339:1992;1-15.
2. Early Breast Cancer Trialist' Collaboration Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339:1992;71-85.
3. Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.
4. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Research. 53:1993;3919-3924.
5. Han X., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Research. 52:1992;1360-1363.
6. Rutqvist L. E., Johansson H., Sognomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87:1995;645-651.
7. Assikis V. J., Neven P., Jordan V. C., Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32A:1996;1464-1476.
8. Gradishar W. J., Jordan V. C. Clinical potential of new antiestrogens. J. Clin. Oncol. 15:1997;840-852.
9. Valavaara R., Pyrohönen S., Heikkenen M., Rissanen P., Blanco G., Thölix E., Nordman E., Taskinen P., Holsti L., Hajba A. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur. J. Cancer Clin. Oncol. 24:1988;785-790.
10. Vogel C. L., Shemano I., Schoenfelder J., Gams R. A., Green M. R. Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 11:1993;345-350.
11. Hayes D. F., Van Zy J. A., Hacking A., Goedhals L., Bezwoda W. R., Mailliard J. A., Jones S. E., Vogel C. L., Berris R. F., Shemano I., Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13:1995;2556-2566.
12. Hard G. C., Iatropoulos M. J., Jordan K., Radi L., Kaltenberg O. P., Imondi A. R., Williams G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Research. 53:1993;4534-4541.
13. Jordan V. C., Assikis V. J. Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin. Cancer Res. 1:1995;467-472.
14. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Research. 56:1996;4374-4377.
15. Carmichael P. L., Ugwumadu A. H.N., Neven P., Hewer A. J., Poon G. K., Phillips D. H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Research. 56:1996;1475-1479.
16. Satyaswaroop P. G., Zaino R. J., Mortel R. Esrogen-like effects of tamoxifen on human endomtrial carcinoma transplanted into nude mice. Cancer Research. 44:1984;4006-4010.
17. Gottardis M. M., Robinson S. P., Satyaswaroop P. G., Jordan V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research. 48:1988;812-815.
18. Tomás E., Kauppila A., Blanco G., Apaja-Sarkkinen M., Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 59:1995;261-266.
19. Bilimoria M. M., Assikis V. J., Muenzner H. D., Wolf D. M., Satyaswaroop P. G., Jordan V. C. An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 58:1996;479-488.
20. Mahfoudi A., Roulet E., Dauvois S., Parker M. G., Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. 92:1995;4206-4210.
21. Webb P., Lopez G. N., Uht R. M., Kushner P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9:1995;443-456.
22. Astruc M. E., Chabret C., Ball P., Gagne D., Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor. Endocrinology. 136:1995;824-832.
23. Dumont J. A., Bitonti A. J., Wallace C. D., Baumann R. J., Cashman E. A., Cross-Doersen D. E. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7:1996;351-359.
24. Dekker L. V., Parker P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 19:1994;73-77.
25. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
26. Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochimica et Biophysica Acta. 1072:1991;129-157.
27. Davidson, N. E. and Kennedy, M. J., Protein kinase C and breast cancer. In Mammary Tumor Cell Cycle, Differentiation and Metastasis, eds. R. Dickson and M. Lippman. Kluwer Academic Publishers, Dordrecht, 1996, pp. 91-105.
28. Jiang S.-Y., Wolf D. M., Yingling J. M., Chang C., Jordan V. C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol. 90:1992;77-86.
29. Pink J. J., Bilimoria M. M., Assikis V., Jordan V. C. Irreversible loss of the estrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br. J. Cancer. 74:1996;1227-1236.
30. Robinson S. P., Jordan V. C. Antiestrogenic action of toremifene on hormone-dependent, independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Research. 49:1989;1758-1762.
31. Tonetti D. A., Horio M., Collart F. R., Huberman E. Protein kinase C β gene expression is associated with susceptibility of human promyelocytic leukemia cells to phorbol ester-induced differentiation. Cell Growth Differ. 3:1992;739-745.
32. Gottardis M. M., Ricchio M. E., Satyaswaroop P. G., Jordan V. C. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Research. 50:1990;3189-3192.
33. 2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int. J. Cancer. 40:1987;344-348.
34. Wyss R., Fabbro D., Regazzi R., Borner C., Takahashi A., Eppenberger U. Phorbol ester and epidermal growth factor receptors in human breast cancer. Anticancer Research. 7:1987;721-728.
35. O'Brian C. A., Vogel V. G., Singletary S. E., Ward N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Research. 49:1989;3215-3217.
36. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur. J. Cancer, 1996, 32A, 2120-2126.
37. Wolf D. M., Jordan V. C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat. 31:1994;117-127.
38. Ways D. K., Kukkoly C. A., deVente J., Hooker J. L., Bryant W. O., Posekany K. J., Fletcher D. J., Cook P. P., Parker P. J. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95:1995;1906-1915.
39. Saarto T., Blomqvist C., Välimäki M., Mäkelä P., Sarna S., Elomaa I. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antiestrogens. Br. J. Cancer. 75:1997;602-605.
40. Saarto T., Blomqvist C., Ehnholm C., Taskinen M.-R., Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 14:1996;429-433.
41. Bamberger A.-M., Bamberger C. M., Wald M., Kratzmeier M., Schulte H. M. Protein kinase C (PKC) isoenzyme expression pattern as an indicator of proliferative activity in uterine tumor cells. Mol. Cell. Endocrinol. 123:1996;81-88.
42. Fujimoto J., Hori M., Ichigo S., Morishita S., Tamaya T. Estrogen induces expression of c-fos and c-jun via activation of protein kinase C in an endometrial cancer cell line and fibroblasts derived from human uterine endometrium. Gynecol. Endocrinol. 10:1996;109-118.
43. Fujimoto J., Hori M., Ichigo S., Morishita S., Tamaya T. Clinical implication of fos and jun expressions and protein kinase activity in endometrial cancers. Eur. J. Gynecol. Oncol. 16:1995;138-146.